A 49-year-old African American man suffering from cutaneous T-cell lymphoma (CTCL) was reported to have developed TdP after receiving the histone deacetylase (HDAC) inhibitor vorinostat for his treatment [11]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.